StreetInsider.com News Articles

NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $42 at RBC Capital

Mon, 05 Oct 2026 08:54:35 -0400

(Updated - October 5, 2026 8:54 AM EDT)

RBC Capital analyst Leonid Timashev lowered the price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) to $42.00 (from $50.00) while maintaining an Outperform rating.

The analyst commented: "See Risk Into Interim, But Remain Confident In Final Analysis; Given the investor focus on NAMS ph.III PREVAIL interim, we took the time to do an in-depth statistical analysis. Our proprietary work finds considerable risk at the interim analysis, largely driven by potentially too few MACE-3 events, and we estimate a 35-38% PoS for PREVAIL's interim. Still, we see a number of potential mitigators, including that

NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $42 at RBC Capital

Mon, 05 Oct 2026 08:54:35 -0400

(Updated - October 5, 2026 8:54 AM EDT)

RBC Capital analyst Leonid Timashev lowered the price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) to $42.00 (from $50.00) while maintaining an Outperform rating.

Form 4 NewAmsterdam Pharma Co For: Sep 30 Filed by: Kastelein Johannes Jacob Pieter

Fri, 02 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261002/27142819.html

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 71,800 of NewAmsterdam’s ordinary shares to 7 non-executive new hires. The share options were granted as an inducement material to the

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

NewAmsterdam Pharma begins Phase 2b trial of obicetrapib in Alzheimer's

Tue, 29 Sep 2026 08:00:42 -0400

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announced the dosing of the first participant in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer's disease, according to a press release dated Sept. 29, 2026.

SPINOZA is a randomized, double-blind, placebo-controlled study targeting approximately 400 participants aged 55 to 85 who have biomarker evidence of early Alzheimer's disease pathology but no noticeable memory or functional symptoms. Eligible participants must carry ApoE4/E4, ApoE3/E4, or ApoE3/E3 genotypes and will be randomized 1:1 to receive obicetrapib 10 mg or placebo for 52 weeks.

The primary endpoint is the change from baseline to Week

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

Tue, 29 Sep 2026 08:00:00 -0400

- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-

- The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures-

NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

Tue, 29 Sep 2026 08:00:00 -0400

- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-

- The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures-

Stifel on NewAmsterdam Pharma Co NV (NAMS): 'the risk/reward is very compelling'

Mon, 21 Sep 2026 10:13:42 -0400

Stifel analyst James Condulis reiterated a Buy rating and $50.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).

The analyst comments "NAMS/Menarini announced obicetrapib--and the ezetimibe FDC--received EU approval. This was expected following the positive CHMP opinion and--though investors aren't focused on the EU near-term--this marks an important milestone for obicetrapib/NAMS. For the stock though, PREVAIL (interim 1Q27) remains most important where there's lingering debate around the implications of the lower-than-expected event rate (especially for MACE-3) in the backdrop of other recent CVOT failures (most notably HORIZON/ Lp(a)). We think these other CVOTs have limited read-through (fundamentally different populations--baseline LDL-C

EU approves NewAmsterdam and Menarini's obicetrapib drugs

Mon, 21 Sep 2026 09:00:55 -0400

The European Commission has granted marketing authorization for two cholesterol-lowering drugs developed by NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) and its partner Menarini Group, marking the first regulatory approval of obicetrapib anywhere in the world.

The approvals cover Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination), both indicated for adults with primary hypercholesterolaemia, including heterozygous familial and non-familial forms, or mixed dyslipidaemia.

The decision follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use and is supported by data from the Phase 3 BROADWAY, BROOKLYN, and TANDEM trials.

EU approves NewAmsterdam and Menarini's obicetrapib drugs

Mon, 21 Sep 2026 09:00:55 -0400

NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

Mon, 21 Sep 2026 09:00:00 -0400

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-

- First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C -

NAARDEN, The Netherlands and MIAMI and FLORENCE, Italy, Sept. 21, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom

NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

Mon, 21 Sep 2026 09:00:00 -0400

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-

- First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C -

NewAmsterdam Pharma CEO buys 10,000 shares at $22.65

Tue, 15 Sep 2026 16:37:08 -0400

Michael H. Davidson, chief executive officer and director of NewAmsterdam Pharma Co N.V. (NASDAQ: NAMS), purchased 10,000 ordinary shares on Sept. 14, 2026, at $22.65 per share, according to a Form 4 filing with the U.S. Securities and Exchange Commission.

Following the transaction, Davidson directly holds 792,923 ordinary shares, which includes 163,352 shares subject to restricted stock unit awards that remain subject to vesting. The filing also notes a prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by Davidson, which had been held by Stichting Administratiekantoor EPNAP for his benefit.

Davidson also indirectly holds 285,715 ordinary shares through

NewAmsterdam Pharma CEO buys 10,000 shares at $22.65

Tue, 15 Sep 2026 16:37:08 -0400

Davidson also indirectly holds 285,715 ordinary shares through

NewAmsterdam Pharma CEO buys 10,000 shares at $22.65

Tue, 15 Sep 2026 16:37:08 -0400

Davidson also indirectly holds 285,715 ordinary shares through

Form 4 NewAmsterdam Pharma Co For: Sep 14 Filed by: Davidson Michael H.

Tue, 15 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260915/27065267.html

NewAmsterdam Pharma Co NV (NAMS) Reiterated at Buy by Stifel

Tue, 08 Sep 2026 06:55:36 -0400

Stifel analyst James Condulis reiterated a Buy rating and $50.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).

The analyst commented, "NVS announced HORIZON failed. There was healthy skepticism after repeated delays--and it's a big reason for NAMS' weakness. Even still, it's a disappointment--that said, our view is: (1) the read-through/implications for PREVAIL are very nuanced; and (2) we don't need to believe much--or anything--from Lp(a) to have confidence in obicetrapib. HORIZON may not have been the best test of the Lp(a) hypothesis, while the populations are entirely different (HORIZON had well-controlled LDL-C--probably why events were low). Moreover--PREVAIL's baseline Lp(a)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 16:01:00 -0400

NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 38,900 of NewAmsterdam’s ordinary shares to five non-executive new hires, as well as inducement share options covering 14,000 ordinary shares to

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 16:01:00 -0400

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

Wed, 02 Sep 2026 08:00:00 -0400

NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

Wed, 02 Sep 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head

NewAmsterdam Pharma (NAMS) call put ratio 1 call to 1 put on 3900 contracts

Mon, 31 Aug 2026 05:32:09 -0400

NewAmsterdam Pharma (NASDAQ: NAMS) 30-day option implied volatility is at 89; compared to its 52-week of 58 to 113. Call put ratio 1 call to 1 put on 3900 contracts.

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Wed, 26 Aug 2026 08:00:00 -0400

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31, 2026 in Munich, Germany.

Presentation details are as follows:

Title: Determinants of Short Term

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Wed, 26 Aug 2026 08:00:00 -0400

Presentation details are as follows:

Title: Determinants of Short Term